Nanopublications LDF server

Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAEjagJ0BR5QpK20oatgavVOfXAzbjqSCMmff1ZjrNUn8#assertion>. }

• association type Statement assertion.
• association label "risedronate sodium tablets usp are a bisphosphonate indicated for treatment and prevention of postmenopausal osteoporosis 1 1 treatment to increase bone mass in men with osteoporosis 1 2 treatment and prevention of glucocorticoid induced osteoporosis 1 3 treatment of paget s disease 1 4 limitations of use optimal duration of use has not been determined for patients at low risk for fracture consider drug discontinuation after 3 to 5 years of use 1 5 risedronate sodium tablets usp are indicated for the treatment and prevention of osteoporosis in postmenopausal women in postmenopausal women with osteoporosis risedronate sodium tablets usp reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis related fractures see clinical studies 14 1 14 2 risedronate sodium tablets usp are indicated for treatment to increase bone mass in men with osteoporosis risedronate sodium tablets usp are indicated for the treatment and prevention of glucocorticoid induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment daily dosage of greater than or equal to 7 5 mg of prednisone or equivalent for chronic diseases patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin d risedronate sodium tablets usp are indicated for treatment of paget s disease of bone in men and women the optimal duration of use has not been determined the safety and effectiveness of risedronate sodium tablets usp for the treatment of osteoporosis are based on clinical data of three years duration all patients on bisphosphonate therapy should have the need for continued therapy re evaluated on a periodic basis patients at low risk for fracture should be considered for drug discontinuation after 3 to 5 years of use patients who discontinue therapy should have their risk for fracture re evaluated periodically" assertion.
• association subject drugbank:DB00884 assertion.
• association predicate treats assertion.
• association object DOID_5408 assertion.
• association relation TreatmentIndication assertion.
• DOID_5408 category Disease assertion.
• drugbank:DB00884 category Drug assertion.
• association association_type ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.
• association provided_by NeuroDKG assertion.